ArticleGland surgery2024
Development and validation of a risk score model for patient stratification and personalized management of papillary thyroid cancer.
Article in Gland surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The status of central lymph node (CLN) is a crucial determinant for the initial treatment of papillary thyroid cancer (PTC), but preoperative ultrasound (US) has limited ability to accurately assess their condition. This study aimed to develop a risk score model for risk stratification of CLN metastasis in unifocal PTC patients to guide the initial treatment. Methods: A total of 5,374 patients diagnosed with unifocal PTC at Union Hospital between November 2009 and August 2022 were finally enrolled in the analysis, including 3,542 patients in derivation cohort and 1,832 patients in validation cohort. Stepwise multivariable logistic regression was used to build the risk score of CLN metastasis. Risk score weights were assigned by dividing the coefficients of the predictors with the lowest coefficient value in the final model and rounding to the nearest integer. Points were calculated for each patient by adding these weights. Results: Ten multivariable predictors constructed the final model, including age, gender, body mass index, Hashimoto's disease, tumor location, calcification, capsule abnormalities, CLN and lateral lymph node (LN) abnormalities and tumor size. Based on the scores derived from these variables, patients were classified into four risk categories: low [0-9], low to intermediate [10-13], intermediate to high [14-17] and high [≥18], corresponding to 20.34%, 37.42%, 59.65%, and 83.82% of the observed incidence of CLN metastasis in the derivation cohort, respectively. In derivation and validation cohorts, the area under the curve of the final model was 0.764 and 0.72, respectively. Conclusions: Compared to relying solely on tumor size and LNs US findings, our risk score, incorporating demographic characteristics and routine pre-operative examinations, served as a more practical and effective tool for risk stratification of CLN metastasis in unifocal PTC patients, facilitating in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.